Explosive Pleurisy Related to Group a Streptococcal Infection: A Case Report and Literature Review
DOI:
https://doi.org/10.17140/PRRMOJ-2-117Keywords:
Explosive pleurisy, Complicated pleural effusion, Empyema, GASAbstract
Group A Streptococcus (GAS) can cause invasive infections, such as pneumonia. It is rarely associated with a rapidly progressing exudative pleural effusion termed “explosive pleurisy”, leading to significant morbidity and mortality. A 27-year-old healthy man devel-oped sore throat 1 week prior to admission and then progressively developed fever, chills and shortness of breath. Upon presentation, his vitals were remarkable for an oral temperature of 102.4 F, blood pressure of 89/64, heart rate of 124, respiratory rate of 40 and a pulse oximeter reading of 84%. Examination revealed pharyngeal erythema and exudates, and decreased right chest expansion with diminished breath sounds and dullness to percussion on the right. Labs revealed leukocytosis of 13,000/mcl White Blood Cells (WBC) (Normal 3,500-10,500 cells/mcl). Chest radiographs showed early pneumonia with a small pleural effusion. A CT scan of the chest was performed 4 hours later, revealing the presence of right middle and lower lobe pneumonia and a moderate-sized pleural effusion. A chest tube was placed and drained serosanguinous fluid. Cultures of the pleural fluid grew GAS. The patient was treated with intravenous Penicillin G and Clindamycin. The patient continued to deteriorate, despite antibiotics and the empyema worsened despite presence of a chest tube. Video Assisted Tho-racoscopic Surgery (VATS) with decortication and drainage was performed with significant improvement of the patient’s condition. GAS pneumonia can progress rapidly with development of complicated parapneumonic effusions and empyema, the so-called ‘explosive pleurisy’. Early surgical intervention may result in quicker symptom resolution and may minimize morbidity.
References
Steer AC, Lamagni T, Curtis N, Carapetis JR. Invasive group a streptococcal disease: epidemiology, pathogenesis and manage-ment. Drugs. 2012; 72(9): 1213-1227. doi: 10.2165/11634180- 000000000-00000
Stevens DL. Streptococcal toxic-shock syndrome: spectrum of disease, pathogenesis, and new concepts in treatment. Emerg Infect Dis. 1995; 1(3): 69-78. doi: 10.3201/eid0103.950301
Barnham M, Weightman N, Anderson A, Pagan F, Chapman S. Review of 17 cases of pneumonia caused by Streptococcus pyogenes. Eur J ClinMicrobiol Infect Dis. 1999; 18(7): 506-509. doi: 10.1007/s100960050333
Braman SS, Donat WE. Explosive pleuritis. manifestation of group A beta-hemolytic streptococcal infection. Am J Med. 1986; 81(4): 723-726. doi: 10.1016/0002-9343(86)90567-X
Johnson JL. Pleurisy, fever, and rapidly progressive pleural ef-fusion in a healthy, 29-year-old physician. Chest. 2001; 119(4): 1266-1269. doi: 10.1378/chest.119.4.1266
Sharma JK, Marrie TJ. Explosive pleuritis. Can J Infect Dis. 2001; 12(2): 104-107.
Stevens DL, Tanner MH, Winship J, et al. Severe group A streptococcal infections associated with a toxic shock-like syndrome and scarlet fever toxin A. N Engl J Med. 1989; 321(1): 1-7. PubMed PMID: 2659990. doi: 10.1056/ NEJM198907063210101
Low DE. Toxic shock syndrome: major advances in patho-genesis, but not treatment. Crit Care Clin. 2013; 29(3): 651-675. doi: 10.1016/j.ccc.2013.03.012
Birch C, Gowardman J. Streptoccocus pyogenes: a forgotten cause of severe community-acquired pneumonia. Anaesth Inten-sive Care. 2000; 28(1): 87-90.
Chapman SJ, Davies RJ. The management of pleural space infections. Respirology. 2004; 9(1): 4-11. doi: 10.1111/j.1440- 1843.2003.00535.x
Rahman NM, Chapman SJ, Davies RJ. Diagnosis and man-agement of infectious pleural effusion. Treat Respir Med. 2006; 5(5): 295-304.
Bagheri R, Tavassoli A, Haghi SZ, et al. The role of thora-coscopic debridement in the treatment of parapneumonic em-pyema. Asian Cardiovasc Thorac Ann. 2013; 21(4): 443-6. doi: 10.1177/0218492312466858
Downloads
Published
How to Cite
Issue
Section
License

This work is licensed under a Creative Commons Attribution 4.0 International License.
All content published in Pulmonary Research and Respiratory Medicine (PRRM) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.